Dong-A ST (A170900) Stock Overview
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 | 
| Future Growth | 3/6 | 
| Past Performance | 0/6 | 
| Financial Health | 3/6 | 
| Dividends | 1/6 | 
Rewards
Risk Analysis
A170900 Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dong-A ST Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩49,300.00 | 
| 52 Week High | ₩75,882.35 | 
| 52 Week Low | ₩40,900.00 | 
| Beta | 0.45 | 
| 1 Month Change | 8.00% | 
| 3 Month Change | 6.71% | 
| 1 Year Change | -34.35% | 
| 3 Year Change | -11.33% | 
| 5 Year Change | -39.09% | 
| Change since IPO | -64.77% | 
Recent News & Updates
Recent updates
Shareholder Returns
| A170900 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.8% | 7.1% | 4.0% | 
| 1Y | -34.4% | 9.7% | 56.8% | 
Return vs Industry: A170900 underperformed the KR Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: A170900 underperformed the KR Market which returned 56.8% over the past year.
Price Volatility
| A170900 volatility | |
|---|---|
| A170900 Average Weekly Movement | 2.9% | 
| Pharmaceuticals Industry Average Movement | 3.8% | 
| Market Average Movement | 4.8% | 
| 10% most volatile stocks in KR Market | 10.4% | 
| 10% least volatile stocks in KR Market | 2.3% | 
Stable Share Price: A170900 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A170900's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website | 
|---|---|---|---|
| 1932 | 1,679 | Jae-Hun Jung | www.donga-st.com | 
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj.
Dong-A ST Co., Ltd. Fundamentals Summary
| A170900 fundamental statistics | |
|---|---|
| Market cap | ₩451.52b | 
| Earnings (TTM) | -₩18.83b | 
| Revenue (TTM) | ₩746.20b | 
Is A170900 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A170900 income statement (TTM) | |
|---|---|
| Revenue | ₩746.20b | 
| Cost of Revenue | ₩402.57b | 
| Gross Profit | ₩343.63b | 
| Other Expenses | ₩362.47b | 
| Earnings | -₩18.83b | 
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06k | 
| Gross Margin | 46.05% | 
| Net Profit Margin | -2.52% | 
| Debt/Equity Ratio | 70.7% | 
How did A170900 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) | 
|---|---|
| Company Analysis | 2025/11/03 00:06 | 
| End of Day Share Price | 2025/11/03 00:00 | 
| Earnings | 2025/06/30 | 
| Annual Earnings | 2024/12/31 | 
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * | 
|---|---|---|---|
| Company Financials | 10 years | 
  | |
| Analyst Consensus Estimates | +3 years | 
  | 
  | 
| Market Prices | 30 years | 
  | |
| Ownership | 10 years | 
  | |
| Management | 10 years | 
  | |
| Key Developments | 10 years | 
  | 
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dong-A ST Co., Ltd. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution | 
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd | 
| Ka-hye Hong | Daishin Securities Co. Ltd. | 
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. | 
